Stock Comparison

INSM vs UTHR

Insmed Inc vs United Therapeutics Corp

The Verdict

INSM takes this one.

Winner

INSM

Insmed Inc

7.3

out of 10

Solid Pick

UTHR

United Therapeutics Corp

5.5

out of 10

Proceed with Caution

Head-to-Head

$35.5B

Market Cap

$25.8B

-25.7

P/E Ratio

19.4

-210.5%

Profit Margin

41.9%

-168.4%

Return on Equity

19.3%

0.8

Debt-to-Equity

N/A

Aggressive

Overall Risk

Moderate

7.3

DVR Score

5.5

The Deep Dive

INSM7.3/10

Insmed (INSM) exhibits strong potential for future market leadership through its innovative pipeline and growing commercial footprint, driving a high growth score. The successful U.S. launch of BRINSUPRI and positive Phase 3b results for ARIKAYCE's ENCORE study are significant de-risking events and catalysts for revenue expansion within substantial addressable markets (NCFBE, IPF). Analyst upgrade...

Full INSM Analysis

UTHR5.5/10

United Therapeutics continues to build on its strong foundation in rare pulmonary diseases with significant recent wins. The TETON-1 pivotal study success for Tyvaso in IPF substantially expands its addressable market and derisks future revenue streams from its core business. Furthermore, the FDA's RMAT designation for miroliverELAP provides a positive signal for its ambitious regenerative medicin...

Full UTHR Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.